Effets de la rosuvastatine sur l’endothélialisation du déviateurs de flux

Intracranial Intracranial aneurysms (IAs), affecting 2-3% of adults, can rupture, causing subarachnoid hemorrhage with high morbidity and mortality. Flow diverters (FDs) treat IAs by reconstructing arteries but face challenges like thromboembolism and incomplete occlusion (up to 20%). Statins may enhance FD outcomes via vascular effects like improved endothelial repair. In a rabbit model, elastase-induced aneurysms were treated with FDs. Rabbits received Rosuvastatin plus Aspirin (ROS+ASA, n=13) or Aspirin alone (ASA, n=9). After two weeks, aneurysm occlusion, branch patency, and endothelialization were assessed. ROS+ASA showed higher occlusion (84.6% vs 66.6%), better branch patency (≥1 mm: 94.4% vs 46.1%, p=0.007), and a superior composite outcome (76.9% vs 22.2%, p=0.011). Endothelial coverage correlated with Rosuvastatin levels (r=0.92, p=0.02). Rosuvastatin improved FD efficacy, suggesting potential for further study.